US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

0.8901

-0.2199-19.81%

Post-market: 0.8134-0.0767-8.62%19:59 EDT

Volume:1.90M

Turnover:1.74M

Market Cap:4.79M

PE:-0.03

High:0.9828

Open:0.9700

Low:0.8303

Close:1.11

Loading ...

Overview Company News Filings

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results

Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook

Cero Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Initiated at Buy by D. Boral Capital

Cero Therapeutics, Inc. Announces up to $8 Million Series D Financing

THOMSON REUTERS

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office

Cero Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances From the U.S. Patent Office Covering Company’s Lead Compound Cer-1236

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236

CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors

MT Newswires Live

Cero Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound Cer-1236 in Solid Tumors

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo enters manufacturing agreement with University of California Davis

Cero Therapeutics Holdings Inc - on Track for First Patient Dosing in H1 2025

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Cero Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement With Contract Research Organization Cellcarta to Manage Translational Assays

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. Highlights Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CERO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":0.8901,"timestamp":1745611200000,"preClose":1.11,"halted":0,"volume":1899600,"hourTrading":{"tag":"盘后","latestPrice":0.8134,"preClose":0.8901,"latestTime":"19:59 EDT","volume":78210,"amount":66264.31186,"timestamp":1745625595902},"delay":0,"floatShares":4381676,"shares":5380723,"eps":-27.83886,"marketStatus":"Not Yet Opened","change":-0.2199,"latestTime":"04-25 16:00:00 EDT","open":0.97,"high":0.9828,"low":0.8303,"amount":1735995.43032,"amplitude":0.137387,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-27.83886,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.11,"preHourTrading":{"tag":"盘前","latestPrice":0.9701,"preClose":1.11,"latestTime":"09:29 EDT","volume":117117,"amount":120383.1706077,"timestamp":1745587795777},"postHourTrading":{"tag":"盘后","latestPrice":0.8134,"preClose":0.8901,"latestTime":"19:59 EDT","volume":78210,"amount":66264.31186,"timestamp":1745625595902},"volumeRatio":0.12846290749776326},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":4381676,"roa":"-178.66%","roe":"--","lyrEps":-38.847442,"volumeRatio":0.12846290749776326,"shares":5380723,"dividePrice":0,"high":0.9828,"amplitude":0.137387,"preClose":1.11,"low":0.8303,"week52Low":0.5338,"pbRate":"-0.94","week52High":171,"institutionHeld":0,"latestPrice":0.8901,"eps":-27.83886,"divideRate":0,"volume":1899600,"delay":0,"ttmEps":-27.83886,"open":0.97,"prevYearClose":6,"prevWeekClose":0.617,"prevMonthClose":0.73,"prevQuarterClose":0.73,"fiveDayClose":0.617,"twentyDayClose":0.765,"sixtyDayClose":1.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530950048","title":"Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530950048","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530950048?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:11","pubTimestamp":1745514680,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44989183/gold-gains-1-bristol-myers-squibb-posts-upbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130103400.USD","LU0130518102.USD","LU0648000940.SGD","LU0985481810.HKD","LU1261432733.SGD","USJW.SI","LU1880383366.USD","LU2108987350.USD","QID","LU0203347892.USD","LU1201861165.SGD","TSYW.SI","SQQQ","LU1585245621.USD","LU1037948897.HKD","CYH","LU0965508806.USD","FI","BK4139","LU0306806265.USD","LU0980610538.SGD","BK4007","LU1291159041.SGD","ASGN","LU0070302665.USD","LU0320765489.SGD","LU0868494617.USD","TMC","LU1670711040.USD","LU0477156953.USD","BMY","BK4204","LU0175139822.USD","LU1868836914.USD","LU1934455863.HKD","QLD","MYE","MNQmain","CERO","LU2125154778.USD","USAW.SI","LU0096364046.USD","TQQQ","NVIW.SI","NQmain",".IXIC","LU0061475181.USD","PSQ"],"gpt_icon":1},{"id":"2529958771","title":"Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529958771","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529958771?lang=en_us&edition=fundamental","pubTime":"2025-04-24 23:06","pubTimestamp":1745507212,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44984387/dow-jumps-over-200-points-pepsico-cuts-earnings-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","NCNA","GNLN","PEP","PCOM","JZXN","XELB","CEP"],"gpt_icon":0},{"id":"2529899399","title":"Cero Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529899399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529899399?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA8SFJZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2529818619","title":"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529818619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529818619?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif, April 24, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute  at Colorado Blood Cancer Institute  in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","CR","ORR","BK4218","CEROW","BK4181","BK4139","PK","CERO"],"gpt_icon":0},{"id":"2529573584","title":"CERo Therapeutics Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529573584","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529573584?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:07","pubTimestamp":1745330820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2025 10:07 ET (14:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CERO","LENZ"],"gpt_icon":0},{"id":"2529057863","title":"Cero Therapeutics, Inc. Announces up to $8 Million Series D Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529057863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529057863?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:15","pubTimestamp":1745324100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA98QTMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2529205306","title":"CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529205306","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529205306?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:15","pubTimestamp":1745324100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif, April 22, 2025  -- CERo Therapeutics Holdings, Inc.  , an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficienci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-inc-announces-8-121500993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4007","CEROW","CERO"],"gpt_icon":0},{"id":"2526459595","title":"BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2526459595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526459595?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:18","pubTimestamp":1744294701,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent OfficeApril 10 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2526656515","title":"Cero Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances From the U.S. Patent Office Covering Company’s Lead Compound Cer-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2526656515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526656515?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:15","pubTimestamp":1744287312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2526256565","title":"CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2526256565","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526256565?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:15","pubTimestamp":1744287300,"startTime":"0","endTime":"0","summary":"Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families. Patent Application No. 17/040,472, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” was allowed on March 13, 2025 and provides coverage for composition of matter and methods of use coverage for the Company’s lead compound, CER-1236. The allowed claims encompass the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is desig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","CERO"],"gpt_icon":0},{"id":"2523929967","title":"CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523929967","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523929967?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434414,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Monday the US Food and Drug Administration has cleared its second investigational new drug application for CER-1236 for a phase 1 trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.\"Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors,\" said Chief Medical Officer Robert Sikorski. AML refers to acute myeloid leukemia.The company said that recent results showed that CER-1236 treated ovarian cancer cells and didn't generate toxicity in mice.Price: 0.76, Change: +0.01, Percent Change: +1.20","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2523946328","title":"Cero Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound Cer-1236 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946328?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423309,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2523794667","title":"CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523794667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523794667?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Food and Drug Administration  for a second Investigational New Drug  application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-receives-121500567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","BK4139","CERO"],"gpt_icon":0},{"id":"2522708653","title":"CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708653?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:15","pubTimestamp":1743077700,"startTime":"0","endTime":"0","summary":"Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology  conference; Continues to be on track to dose first patient in first half of 2025. SOUTH SAN FRANSCISCO, Calif., March 27, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received positive review from the U.S. Food and Drug Administration  on an amendment to its IND around Chemistry, Manufacturing and Controls , which marks completion of the Company’s final commitment to FDA prior to initiating patient dosing and shortens the manufacturing timeline by about a week. With this completion, the Company is on track to meet its anticipated timeline of dosing initial subjects during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-poised-121500919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0882574139.USD","LU1363072403.SGD","IE00B1BXHZ80.USD","BK4161","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","LU0267386448.USD","CEROW","BK4006","BK4218","IE00BKVL7J92.USD","BK4181","CR","LU0149725797.USD","LU0971096721.USD","LU0170899867.USD","ORR","PK","CERO","CMC"],"gpt_icon":0},{"id":"2520186152","title":"CERo enters manufacturing agreement with University of California Davis","url":"https://stock-news.laohu8.com/highlight/detail?id=2520186152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520186152?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:20","pubTimestamp":1742386849,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-enters-manufacturing-agreement-with-university-of-california-davis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-enters-manufacturing-agreement-with-university-of-california-davis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2520855011","title":"Cero Therapeutics Holdings Inc - on Track for First Patient Dosing in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520855011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520855011?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:15","pubTimestamp":1742386500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA36LZ9D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2519315839","title":"CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2519315839","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519315839?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif., March 13, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.In the poster, titled, “TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators demonstrated that CER-1236treated ovarian cancer cells and did not generate toxicity in animal models . Investigators found that following dosing, assessment of clinical and anatomic pathology after CER-1236 infusion showed T cell engraftment in lymphoid organs, but there were no in-life observations, clinical pathology, nor histopathological evaluations indicating toxicity caused by the compound.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-presents-121500350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","CEROW"],"gpt_icon":0},{"id":"2517315267","title":"Cero Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement With Contract Research Organization Cellcarta to Manage Translational Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2517315267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517315267?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:15","pubTimestamp":1741266926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP0GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2517152714","title":"CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2517152714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517152714?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:15","pubTimestamp":1741266900,"startTime":"0","endTime":"0","summary":"Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells . CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor  cell therapy, as the use of CER-T may potentiall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-131500341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU2065732104.USD","PRGS","BK4139","CEROW","CERO"],"gpt_icon":0},{"id":"2509275525","title":"CERo Therapeutics Holdings, Inc. Highlights Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275525","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275525?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:15","pubTimestamp":1738847700,"startTime":"0","endTime":"0","summary":"Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025. CEO Chris Ehrlich commented, “We have had a very strong entry into 2025, which has greatly improved the outlook of the Company from the previous year. As announced, we completed a $5 million financing, which gives us a current cash position of approximately $8 million. We believe this funding will allow us to achieve numerous value-creating milestones in the coming year. In addition, we have also completed the conversion of the majority of our preferred shares into common shares, which significantly improves our cap table moving forward.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is desig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-highlights-131500688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU2065732104.USD","CERO","CEROW","PRGS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-04-25","current":-0.719207,"percent":0.776978,"low":-23.40166,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"high":-0.137942,"avg":-4.508078,"sd":5.013125,"marketCap":5972602},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602}],"updateTime":1745794867921}}}